비임상시험 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 시험 유형별, 시험별, 치료 영역별, 최종사용자별, 지역별, 경쟁별 부문,2020-2030연대

Non-Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Study Type, By Test, By Therapeutic Area, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,511,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,957,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,575,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

비임상시험 시장 규모는 2024년에 113억 6,000만 달러로, 예측 기간에는 169억 5,000만 달러에 달할 것으로 예측되며, 2030년까지 CAGR은 6.87%입니다.

세계의 비임상시험 시장은 제약 및 헬스케어 산업의 역동적이고 필수적인 컴포넌트이며, 신약 및 의료기기의 개발 및 승인에 있으며, 매우 중요한 역할을 담당하고 있습니다. 이 시장에는 잠재적인 치료법이나 치료법이 인체 실험에 들어가기 전에 수행되는 광범위한 활동이 포함됩니다. 흔히 전임상시험이라고 불리는 비임상시험은 실험용 의약품 및 의료 제품의 안전성, 유효성, 독성을 평가하기 위해 동물, 시험관내 시스템, 컴퓨터 시뮬레이션을 사용하여 수행되는 일련의 엄격한 시험 및 평가를 포함합니다. 세계 비임상시험 시장 성장의 주요 촉진요인 중 하나는 수많은 건강 상태와 질병을 치료하기 위한 혁신적인 의약품과 의료기기에 대한 수요가 지속적으로 증가하고 있다는 점입니다. 이에 따라 제약회사, 바이오테크놀러지 기업 및 학술연구기관은 자사 제품이 규제 기준을 충족하고 인간에게 안전하게 사용될 수 있도록 비임상시험에 많은 투자를 하고 있습니다. 이에 따라 비임상시험 서비스를 전문 개발업무수탁기관(CRO)에 위탁하는 움직임이 급증하면서 시장 확대에 박차를 가하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	113억 6,000만 달러
시장 규모 : 2030년	169억 5,000만 달러
CAGR : 2025-2030년	6.87%
급성장 부문	제약·바이오테크놀러지 기업
최대 시장	북미

시장 성장 촉진요인

혁신적인 의약품과 의료기기에 대한 수요 증가

주요 시장이 해결해야 할 과제

엄격한 규제 준수

주요 시장 동향

혁신적 치료법의 부상

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 세계의 비임상시험 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 연구 유형별(약력학(PD) 연구, 약물 동태(PK) 연구, 독성학 연구)
  • 테스트별(In silico, In vitro, In vivo)
  • 치료 영역별(종양학, 순환기학, 신경학, 면역학, 기타)
  • 최종사용자별(제약회사, 바이오테크놀러지 기업, 개발 조사 수탁 기관(CRO), 학술기관 및 정부 조사기관, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵
  • 연구 유형별
  • 테스트별
  • 치료 영역별
  • 최종사용자별
  • 지역별

제5장 아시아태평양의 비임상시험 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 연구 유형별
  • 테스트별
  • 치료 영역별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 비임상시험 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 비임상시험 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
  • 연구의 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 비임상시험 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 비임상시험 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제10장 시장 역학

• 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제12장 세계의 비임상시험 시장 : SWOT 분석

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Labcorp Drug Development
• Charles River Laboratories
• PPD(Pharmaceutical Product Development)
• ICON plc
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• CMIC HOLDINGS Co., LTD
• ProPharma
• MorphoSys AG

제15장 전략적 제안

제16장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

Global Non-Clinical Trials Market was valued at USD 11.36 Billion in 2024 and is expected to reach USD 16.95 Billion in the forecast period with a CAGR of 6.87% through 2030. The Global Non-Clinical Trials Market represents a dynamic and essential component of the pharmaceutical and healthcare industries, playing a pivotal role in the development and approval of new drugs and medical devices. This market encompasses a wide range of activities that occur before a potential treatment or therapy is tested on human subjects. Non-clinical trials, often referred to as preclinical trials, involve a series of rigorous tests and evaluations conducted on animals, in vitro systems, or computer simulations to assess the safety, efficacy, and toxicity of experimental drugs and medical products. One of the key drivers behind the growth of the global non-clinical trials market is the ever-increasing demand for innovative pharmaceuticals and medical devices to address a myriad of health conditions and diseases. As a result, pharmaceutical and biotechnology companies, as well as academic research institutions, are heavily invested in non-clinical trials to ensure that their products meet regulatory standards and are safe for human use. This has led to a surge in the outsourcing of non-clinical trial services to specialized contract research organizations (CROs), further fueling market expansion.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 11.36 Billion
Market Size 2030	USD 16.95 Billion
CAGR 2025-2030	6.87%
Fastest Growing Segment	Pharmaceutical and Biotechnology Companies
Largest Market	North America

Key Market Drivers

Rising Demand for Innovative Pharmaceuticals and Medical Devices

The global demand for innovative pharmaceuticals and medical devices is a primary driver behind the robust growth of the Global Non-Clinical Trials Market. As the global population ages and the prevalence of chronic diseases continues to escalate, there is an increasing need for cutting-edge therapies and medical solutions. This burgeoning demand has propelled pharmaceutical and biotechnology companies, as well as academic research institutions, into an intense race to develop new drugs and devices that address a wide spectrum of health conditions.

Non-clinical trials, also known as preclinical trials, are instrumental in meeting this demand by providing a crucial testing ground for these innovative products before they advance to human clinical trials. These trials involve comprehensive assessments of safety, efficacy, and toxicity, which are essential for regulatory approval and eventual market access. In 2023, research and development spending in the pharmaceutical industry exceeded USD 300 billion globally, highlighting the industry's commitment to innovation and the critical role of non-clinical trials in the drug development process.

Key Market Challenges

Stringent Regulatory Compliance

Complex and Evolving Regulations: Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have developed comprehensive guidelines that govern non-clinical trials. However, these regulations are intricate, subject to frequent updates, and can vary from one region to another. Navigating this complex regulatory landscape demands substantial expertise and resources, which can slow down the initiation and progression of non-clinical trials. Stringent Data and Documentation Requirements: Regulatory authorities require extensive documentation and data to support non-clinical trial submissions. Researchers must meticulously document every aspect of the trial, from study design and procedures to results and statistical analyses. This demanding documentation process can be time-consuming and resource-intensive, diverting valuable time and resources away from research activities.

Ethical and Patient Safety Considerations: Regulatory compliance often entails rigorous ethical considerations and a focus on patient safety. These ethical standards necessitate adherence to guidelines that protect the welfare of research subjects, whether they are animals or humans. Ensuring compliance with these ethical standards can lead to additional hurdles and delays, particularly when addressing the safety and well-being of trial participants. Meeting regulatory compliance requirements is resource-intensive. Companies and research organizations must invest in state-of-the-art facilities, skilled personnel, and advanced technologies to conduct non-clinical trials that satisfy regulatory standards.

Key Market Trends

Rise in Innovative Therapies

The Global Non-Clinical Trials Market is experiencing a substantial boost due to the relentless rise in demand for innovative therapies. As the global population grapples with an increasing burden of diseases, there has been an unmistakable call for transformative pharmaceuticals and medical devices to address these health challenges. This insatiable demand for groundbreaking treatments has spurred pharmaceutical and biotechnology companies, as well as academic research institutions, to intensify their research and development efforts. Consequently, non-clinical trials have taken center stage as a pivotal phase in the development of these innovative therapies.

In the current landscape, innovative therapies encompass a wide spectrum of cutting-edge approaches, including precision medicine, gene therapies, immunotherapies, and targeted therapeutics, among others. These novel treatments hold the promise of offering highly effective and personalized solutions for a range of health conditions, from rare genetic disorders to complex cancers. However, before these therapies can advance to human clinical trials and eventually reach patients, they must undergo rigorous assessment in non-clinical trials.

Key Market Players

• Labcorp Drug Development
• Charles River Laboratories
• PPD (Pharmaceutical Product Development)
• ICON plc
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• Cmic Holdings Co., Ltd
• ProPharma
• MorphoSys AG

Report Scope:

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Clinical Trials Market, By Study Type:

• Pharmacodynamics (PD) studies
• Pharmacokinetics (PK) studies
• Toxicology studies

Non-Clinical Trials Market, By Test:

• In silico
• In vitro
• In vivo

Non-Clinical Trials Market, By Therapeutic Area:

• Oncology
• Cardiovascular
• Neurology
• Immunology
• Others

Non-Clinical Trials Market, By End User:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Government Research Institutes
• Others

Non-Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

Global Non-Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Clinical Trials Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
  • 4.2.2. By Test (In silico, In vitro, In vivo )
  • 4.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
  • 4.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others )
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Study Type
  • 4.3.2. By Test
  • 4.3.3. By Therapeutic Area
  • 4.3.4. By End User
  • 4.3.5. By Region

5. Asia Pacific Non-Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Type
  • 5.2.2. By Test
  • 5.2.3. By Therapeutic Area
  • 5.2.4. By End User
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Non-Clinical Trials Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Study Type
      • 5.3.1.2.2. By Test
      • 5.3.1.2.3. By Therapeutic Area
      • 5.3.1.2.4. By End User
  • 5.3.2. India Non-Clinical Trials Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Study Type
      • 5.3.2.2.2. By Test
      • 5.3.2.2.3. By Therapeutic Area
      • 5.3.2.2.4. By End User
  • 5.3.3. Australia Non-Clinical Trials Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Study Type
      • 5.3.3.2.2. By Test
      • 5.3.3.2.3. By Therapeutic Area
      • 5.3.3.2.4. By End User
  • 5.3.4. Japan Non-Clinical Trials Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Study Type
      • 5.3.4.2.2. By Test
      • 5.3.4.2.3. By Therapeutic Area
      • 5.3.4.2.4. By End User
  • 5.3.5. South Korea Non-Clinical Trials Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Study Type
      • 5.3.5.2.2. By Test
      • 5.3.5.2.3. By Therapeutic Area
      • 5.3.5.2.4. By End User

6. Europe Non-Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Type
  • 6.2.2. By Test
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Non-Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Type
      • 6.3.1.2.2. By Test
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Germany Non-Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Type
      • 6.3.2.2.2. By Test
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Spain Non-Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Type
      • 6.3.3.2.2. By Test
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User
  • 6.3.4. Italy Non-Clinical Trials Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Study Type
      • 6.3.4.2.2. By Test
      • 6.3.4.2.3. By Therapeutic Area
      • 6.3.4.2.4. By End User
  • 6.3.5. United Kingdom Non-Clinical Trials Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Study Type
      • 6.3.5.2.2. By Test
      • 6.3.5.2.3. By Therapeutic Area
      • 6.3.5.2.4. By End User

7. North America Non-Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. Study Type
  • 7.2.3. By End User
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Non-Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Type
      • 7.3.1.2.2. By Test
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Mexico Non-Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Type
      • 7.3.2.2.2. By Test
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. Canada Non-Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Type
      • 7.3.3.2.2. By Test
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User

8. South America Non-Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Type
  • 8.2.2. By Test
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Non-Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Type
      • 8.3.1.2.2. By Test
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. Argentina Non-Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Type
      • 8.3.2.2.2. By Test
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Colombia Non-Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Type
      • 8.3.3.2.2. By Test
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User

9. Middle East and Africa Non-Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Non-Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Type
      • 9.3.1.2.2. By Test
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Saudi Arabia Non-Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. UAE Non-Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Type
      • 9.3.3.2.2. By Test
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Non-Clinical Trials Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Labcorp Drug Development
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Charles River Laboratories
• 14.3. PPD (Pharmaceutical Product Development)
• 14.4. ICON plc
• 14.5. Novartis AG
• 14.6. Merck & Co., Inc.
• 14.7. AstraZeneca plc
• 14.8. CMIC HOLDINGS Co., LTD
• 14.9. ProPharma
• 14.10.MorphoSys AG

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료